ORIC - ORIC Pharmaceuticals

-

$undefined

N/A

(N/A)

ORIC Pharmaceuticals NasdaqGS:ORIC ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Location: 240 East Grand Avenue, 2Nd Floor, South San Francisco, CA, 94080, United States | Website: https://www.oricpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

141.2M

Cash

203.7M

Avg Qtr Burn

-28.75M

Short % of Float

21.35%

Insider Ownership

9.56%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ORIC-114 Details
Cancer, 1L Non-small cell lung carcinoma

Phase 3

Initiation

ORIC-114 Details
Solid tumor/s, Advanced malignancies, Cancer

Phase 1b

Data readout

ORIC-944 Details
Prostate cancer, Cancer

Phase 1b

Data readout

ORIC-533 Details
Multiple myeloma, Cancer

Phase 1b

Update

Failed

Discontinued

ORIC-101 and nab-paclitaxel Details
Solid tumor/s, Muscle control disorder, Spasticity, Cancer

Failed

Discontinued